Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The standard treatment of local advanced cervical cancer is concurrent chemoradiotherapy. The
3 year disease free survival was about 50-70%. The distant metastasis is the main cause of
failure in local advanced cervical cancer treated with 3-dimensional conformal radiotherapy
(3D-CRT) or intensity modulated radiotherapy (IMRT). The purpose of this study is to
investigate the efficacy and tolerance of concurrent and adjuvant chemotherapy with cisplatin
and docetaxel for local advanced cervical cancer. It was expected that the 3 year disease
free survival would be increased by 10% with this new treatment schedule.
Phase:
Phase 3
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University